DiFusion Technologies, an industry leader in advanced biomaterials for surgical implants, announced today the issuance of a new US Patent 12,178,936 B2 “Medical Implants and Methods of Manufacture.”
The new patent encompasses four methods to manufacture ZFUZE a proprietary therapeutic, anti-inflammatory, osseoconductive, load bearing biomaterial for orthopedic implants. ZFUZE is the first FDA-cleared advanced biomaterial for spinal implants that is proven to create a highly favorable cellular and immunologic response post-surgery. A recent finding is from a 75 patient retrospective study, whereby ZFUZE posted a dominant 93.4% lumbar spinal fusion rate at 6 months while similar competitive studies demonstrate average lumbar fusion rates of 68% at 12 months.
“This new patent firmly protects our ZFUZE FDA Master File for another 17 years. ZFUZE is the only FDA cleared immuno-modulating biomaterial currently available to patients’ surgeons and hospitals,” DiFusion Founder and CEO Derrick Johns. “Building a FDA Master File is a long, arduous and expensive process that larger orthopedic companies are not scientifically equipped to execute,” added Johns.
